• GRAIL announced that the FDA’s Molecular and Clinical Genetics Panel will meet on September 23, 2026, to review its Premarket Approval application for the Galleri multi-cancer early detection blood test, which uses methylation patterns and artificial intelligence to detect cancer signals and predict their origin alongside existing screening methods.
• The PMA filing leans on extensive data from the PATHFINDER 2 study of 25,490 U.S. participants and over 70,000 participants from the NHS-Galleri trial, underscoring Galleri’s unique position as the only multi-cancer early detection test evaluated in large interventional and randomized, controlled intended-use populations.
• With an FDA advisory panel review now scheduled for Galleri’s PMA, we’ll examine how this regulatory milestone reshapes GRAIL’s investment narrative.

Find 52 companies with promising cash flow potential yet trading below their fair value.

GRAIL Investment Narrative Recap

To own GRAIL, you need to believe multi cancer early detection can become a routine part of screening and that Galleri’s data package can underpin durable adoption. The newly scheduled FDA advisory panel on September 23, 2026 is now the key near term catalyst, while continued heavy losses and uncertain reimbursement remain the biggest risks. This meeting date is clearly material because it crystallizes the regulatory timeline that underpins most revenue expectations.

The most relevant recent update alongside the panel news is GRAIL’s Q2 2026 earnings. Revenue rose to US$44.69 million, while net loss remained large at US$110.25 million. This combination of growing sales and substantial ongoing cash burn frames how important the upcoming FDA and payer decisions are. Without clearer regulatory and coverage visibility around Galleri, it is harder to see how the business model can eventually support these operating losses.

Yet behind the optimism about Galleri’s potential, one issue investors should be aware of is the risk that payer coverage decisions could...

GRAIL's narrative projects $320.3 million revenue and $60.8 million earnings by 2029. This requires 27.1% yearly revenue growth and a $456.1 million earnings increase from -$395.3 million today.

Uncover how GRAIL's forecasts yield a $66.00 fair value, a 5% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming revenue could reach about US$390.0 million by 2029, which is far more aggressive than consensus and puts heavy weight on successful FDA approval and Medicare coverage that the recent panel date could help frame, even as the NHS Galleri trial’s missed primary endpoint highlights how sharply opinions on risk and reward can differ.

Explore 5 other fair value estimates on GRAIL - why the stock might be worth less than half the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your GRAIL research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free GRAIL research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate GRAIL's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.